Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30865387,urine levels,"Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold.","Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865387/),[ng] / [ml],1.96,2414,DB01274,Arformoterol
,30865387,urine levels,"Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold.","Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865387/),[ng] / [ml],1.67,2415,DB01274,Arformoterol
,30865387,urine levels,"Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold.","Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865387/),[ng] / [ml],0.45,2416,DB01274,Arformoterol
,30865387,urine levels,"Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold.","Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865387/),[ng] / [ml],0.61,2417,DB01274,Arformoterol
,30865387,urine levels,"Total (free drug plus conjugated metabolite) median (min-max) rac-formoterol urine levels following inhalation were 1.96 (1.05-13.4) ng/mL, 1.67 (0.16-9.67) ng/mL, 0.45 (0.16-1.51) ng/mL, 0.61 (0.33-0.78) ng/mL, and 0.17 (0.08-1.06) ng/mL at 2, 4, 8, 12, and 24 hours, respectively, well below the 2019 urine threshold.","Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30865387/),[ng] / [ml],0.17,2418,DB01274,Arformoterol
,22843108,urine concentration,"Median urine concentration, corrected for specific gravity, after the single-dose administration peaked during 0-4 h after inhalation at a maximum of 7.4 ng·mL(-1) in asthmatic subjects and 7.9 ng·mL(-1) in healthy subjects.",Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],7.4,11050,DB01274,Arformoterol
,22843108,urine concentration,"Median urine concentration, corrected for specific gravity, after the single-dose administration peaked during 0-4 h after inhalation at a maximum of 7.4 ng·mL(-1) in asthmatic subjects and 7.9 ng·mL(-1) in healthy subjects.",Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],7.9,11051,DB01274,Arformoterol
,22843108,maximum individual concentration,The maximum individual concentration of 25.6 ng·mL(-1) was found after inhalation of a total of 72 μg formoterol.,Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22843108/),[ng] / [ml],25.6,11052,DB01274,Arformoterol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14022,DB01274,Arformoterol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14023,DB01274,Arformoterol
,18518793,Retention,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14024,DB01274,Arformoterol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14025,DB01274,Arformoterol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.19,14026,DB01274,Arformoterol
,18518793,fraction of deposited dose,"Retention in lung tissues at the end of the perfusion period expressed as fraction of deposited dose was 0.19 +/- 0.05, 0.19 +/- 0.06, and 0.04 +/- 0.01 (mean +/- SD, n = 3) for budesonide, formoterol, and terbutaline, respectively.","Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18518793/),,0.04,14027,DB01274,Arformoterol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],64,17873,DB01274,Arformoterol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],56,17874,DB01274,Arformoterol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],79,17875,DB01274,Arformoterol
,24978441,inspiratory flow rates,"Mean inspiratory flow rates through EH were 64 and 56 L/min in asthmatics and COPD patients, and through TH 79 and 72 L/min, respectively.",Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler(®). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24978441/),[l] / [min],72,17876,DB01274,Arformoterol
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],5280,24541,DB01274,Arformoterol
,19650674,area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)],"Exposure to BDP was not significantly different between active treatment arms, but lower systemic exposure to B17MP was observed with the fixed combination than with the separate components (area under the plasma concentration-time curve [AUC] from time zero to infinity [AUC(infinity)] 5280 vs 8120 pg.h/mL; p = 0.001).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],8120,24542,DB01274,Arformoterol
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],353,24543,DB01274,Arformoterol
,19650674,AUC from 0 to 30 minutes [AUC(30 min)],"Despite a lower total systemic exposure to B17MP with the fixed combination, B17MP plasma concentrations during the first 30 minutes after administration, indicative of pulmonary absorption, were 86% higher with BDP/F than with the separate components (AUC from 0 to 30 minutes [AUC(30 min)] 353 vs 190 pg x h/mL; p = 0.003).",Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19650674/),[h·pg] / [ml],190,24544,DB01274,Arformoterol
,18655841,AUC(0-12),"Mean FEV(1) AUC(0-12) following FFIS treatment ranged from 1.3 to 3.0l/h in a dose-related manner, with equivalent values (2.3l/h) for FFIS 20microg and FA.",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),[l] / [h],1.3 to 3.0,46456,DB01274,Arformoterol
,18655841,AUC(0-12),"Mean FEV(1) AUC(0-12) following FFIS treatment ranged from 1.3 to 3.0l/h in a dose-related manner, with equivalent values (2.3l/h) for FFIS 20microg and FA.",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),[l] / [h],2.3,46457,DB01274,Arformoterol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,3.9,46458,DB01274,Arformoterol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,2.2,46459,DB01274,Arformoterol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),%,15,46460,DB01274,Arformoterol
,18655841,time to onset of bronchodilation,"Study results with the nebulized formulation supported the rapid time to onset of bronchodilation with FFIS 20microg (3.9 and 2.2min imputed for 15% and 12%/200ml response, respectively).",Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),%,12,46461,DB01274,Arformoterol
,18655841,T(max),FFIS 244mug was rapidly absorbed with a T(max) of 12min and t(1/2) of 6.1h.,Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),min,12,46462,DB01274,Arformoterol
,18655841,t(1/2),FFIS 244mug was rapidly absorbed with a T(max) of 12min and t(1/2) of 6.1h.,Nebulized formoterol fumarate: Dose selection and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655841/),h,6.1,46463,DB01274,Arformoterol
<,15031566,onset of action,Formoterol demonstrated an onset of action of <3 min.,Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15031566/),min,3,54161,DB01274,Arformoterol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.4,54760,DB01274,Arformoterol
,16303295,minimum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),[mM] / [l],3.3,54761,DB01274,Arformoterol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,9.0,54762,DB01274,Arformoterol
,16303295,maximum,"Both agents were associated with decreased plasma potassium (mean minimum values: 3.4 and 3.3 mmol/l for formoterol and salbutamol, respectively; P=0.914), increased serum glucose (mean maximum values: 9.0 and 8.7 mmol/l, respectively; P=0.373), and small increases in mean QTc interval (mean maximum 439 ms with both treatments; P=0.813).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),,8.7,54763,DB01274,Arformoterol
,16303295,maximum forced expiratory volume,"Both drugs improved lung function (mean maximum forced expiratory volume in 1s [FEV(1)] 2.6 l with both treatments; P=0.624), with the improvement being significantly greater with formoterol than with salbutamol on all 3 days of treatment (mean area under the curve [AUC](0-24 h) of FEV(1) formoterol vs. salbutamol on days 1-3, all P<0.05).",Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303295/),l,2.6,54764,DB01274,Arformoterol
,9776436,Ka,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),1/[h],6.9,61263,DB01274,Arformoterol
,9776436,t1/2,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),h,8.5,61264,DB01274,Arformoterol
,9776436,AUC,"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),[pg] / [h·l],741,61265,DB01274,Arformoterol
,9776436,V(area/f),"The values of the kinetic parameters were: Ka: 6.9 (h(-1)), t1/2, 8.5 (h), AUC: 741 (pg x h(-1) x l(-1), V(area/f): 1470 (l).",Pharmacokinetics and effects of formoterol fumarate in healthy human subjects after oral dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776436/),l,1470,61266,DB01274,Arformoterol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),l,1.38,62345,DB01274,Arformoterol
,11601748,forced expiratory volume in 1 sec (FEV1),"A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted].",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),%,45.8,62346,DB01274,Arformoterol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62347,DB01274,Arformoterol
,11601748,area under the curve (AUC),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62348,DB01274,Arformoterol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],5.89,62349,DB01274,Arformoterol
,11601748,AUC(0-30 min),"The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)).",Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11601748/),[l] / [min],6.06,62350,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],811.8,74209,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1748,74210,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],224.3,74211,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],459.3,74212,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],1250,74213,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],2510,74214,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],315.4,74215,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, budesonide AUC0-12 and Cmax were increased dose proportionally from BGF MDI 160/14.4/10 μg to BGF MDI 320/14.4/10 μg, respectively (single dose: AUC0-12, 811.8 vs 1748 h · pg/mL; Cmax, 224.3 vs 459.3 pg/mL; repeated dosing: AUC0-12, 1250 vs 2510 h · pg/mL; Cmax, 315.4 vs 626.4 pg/mL).","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],626.4,74216,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],27.20-29.40,74217,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],4.884-5.674,74218,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],69.49-77.08,74219,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],11.30-13.12,74220,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],46.49-53.58,74221,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],9.651-10.62,74222,DB01274,Arformoterol
,30982547,AUC0-12,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[h·pg] / [ml],81.94-85.32,74223,DB01274,Arformoterol
,30982547,Cmax,"After single and repeated dosing, glycopyrronium AUC0-12 and Cmax were similar across all treatments (single dose: AUC0-12, 27.20-29.40 h · pg/mL; Cmax, 4.884-5.674 pg/mL; repeated dosing: AUC0-12, 69.49-77.08 h · pg/mL; Cmax, 11.30-13.12 pg/mL) and formoterol (single dose: AUC0-12, 46.49-53.58 h · pg/mL; Cmax 9.651-10.62 pg/mL; repeated dosing: AUC0-12, 81.94-85.32 h · pg/mL; Cmax, 16.13-17.71 pg/mL), suggesting that the addition of budesonide did not appreciably alter the PK properties of GFF MDI.","Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30982547/),[pg] / [ml],16.13-17.71,74224,DB01274,Arformoterol
,12236843,total urinary excretion,The median (range) of the total urinary excretion of formoterol was 37.8% (20.9-51.2%) of the dose.,Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,37.8,95229,DB01274,Arformoterol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,2.1,95230,DB01274,Arformoterol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,3.5,95231,DB01274,Arformoterol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,21.0,95232,DB01274,Arformoterol
,12236843,excre,"The medians (ranges) of the amounts of (R; R)- and (S; S)-formoterol and of (R; R)- and (S; S)-formoterol glucuronide excreted were 2.1 (1.0-2.9), 3.5 (2.6-3.8), 21.0 (13.1-31.0) and 10.3 (4.2-14.6)%, respectively, of the dose.",Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12236843/),%,10.3,95233,DB01274,Arformoterol
,10516540,reversibility,"In a double-blind, randomized, crossover and placebo-controlled study design, the respiratory functions of 22 patients (mean age 57.3+/-5.4 years) having mild to severe COPD (5 mild, 8 moderate and 9 severe) and partially reversible airway obstruction [mean baseline reversibility of forced expiratory volume in 1 s (FEV(1)) 19.3+/-3.1%] were evaluated after inhalation of 12 microg formoterol and 50 microg salmeterol.","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),%,19.3,95418,DB01274,Arformoterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.39,95419,DB01274,Arformoterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.40,95420,DB01274,Arformoterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.02,95421,DB01274,Arformoterol
,10516540,peak bronchodilator effects,"The peak bronchodilator effects occurring at 60 and 120 min following formoterol (0.39 liters) and salmeterol (0.40 liters) inhalation, respectively, were significantly higher than the corresponding levels of placebo (0.02 and -0.12 liters, respectively).","Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),l,0.12,95422,DB01274,Arformoterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.5,95423,DB01274,Arformoterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,3.2,95424,DB01274,Arformoterol
,10516540,area under the curve,The area under the curve values of FEV(1) of formoterol (3.5+/-1.3 l.h) and salmeterol (3.2+/-1.2 l x h) averaged over 12 h were comparable and higher than placebo values (1.2+/-0.5 l x h).,"Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10516540/),h·l,1.2,95425,DB01274,Arformoterol
,27138024,Cmax,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[pg] / [ml],270,96884,DB01274,Arformoterol
,27138024,Cmax,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[pg] / [ml],215,96885,DB01274,Arformoterol
,27138024,AUC0-t,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[h·pg] / [ml],229,96886,DB01274,Arformoterol
,27138024,AUC0-t,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[h·pg] / [ml],222,96887,DB01274,Arformoterol
,27138024,Cmax,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[pg] / [ml],11,96888,DB01274,Arformoterol
,27138024,Cmax,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[pg] / [ml],9.3,96889,DB01274,Arformoterol
,27138024,AUC,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[h·pg] / [ml],36,96890,DB01274,Arformoterol
,27138024,AUC,"The rate and extent of absorption were comparable for aclidinium/formoterol FDC and individual monotherapies; aclidinium/formoterol FDC and aclidinium alone: Cmax , 270 and 215 pg/mL, respectively; AUC0-t , 229 and 222 pg · h/mL, respectively; aclidinium/formoterol FDC and formoterol alone: Cmax , 11 and 9.3 pg/mL, respectively; AUC, 36 and 32.4 pg · h/mL, respectively.","Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138024/),[h·pg] / [ml],32.4,96891,DB01274,Arformoterol
<,15741775,onset of action,The onset of action of formoterol was <3 min for all active treatments.,Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15741775/),min,3,103271,DB01274,Arformoterol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.57,114020,DB01274,Arformoterol
,19537837,AUC(0-3),"At 6 weeks, FEV(1) AUC(0-3) was significantly greater in the formoterol group compared with the placebo group (1.57 vs 1.38 L [p < 0.0001]).","Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19537837/),l,1.38,114021,DB01274,Arformoterol
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],2.29,115359,DB01274,Arformoterol
,10419838,E max,The E max values+/-SD for the hypokalemic effects were 2.29+/-0.78 mmol/l for formoterol and 1.64+/-1.16 mmol/l for theophylline (P>0.05).,Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[mM] / [l],1.64,115360,DB01274,Arformoterol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],91.4,115361,DB01274,Arformoterol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[pg] / [ml],128.4,115362,DB01274,Arformoterol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],11. 9,115363,DB01274,Arformoterol
,10419838,EC 50,"The EC 50 values of the eosinopenic and hypokalemic effects were respectively 91.4+/-38.2 pg/ml and 128.4+/-52.9 pg/ml for formoterol, and 11. 9+/-4.6 microg/ml and 15.5+/-4.8 microg/ml for theophylline.",Pharmacokinetic/pharmacodynamic modelling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination in healthy men. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10419838/),[μg] / [ml],15.5,115364,DB01274,Arformoterol
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,152,118532,DB01274,Arformoterol
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,240,118533,DB01274,Arformoterol
,32253054,space,"For systemic exposure (without charcoal), the spacer/without spacer ratio, expressed as a percentage (intrasubject %CV) of Cmax and AUC0-tlast, respectively, was 152.0 (47.5) and 132.8 (43.6) for budesonide, 240.6 (80.2) and 154.7 (73.4) for glycopyrronium, and 165.6 (50.7) and 98.6 (53.8) for formoterol.","Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32253054/),,165,118534,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],2822.3,128799,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],5454.9,128800,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],771.6,128801,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],1138.9,128802,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],38.4,128803,DB01274,Arformoterol
,21615456,peak plasma concentrations (C(max)),"Compared with pMDI alone, use of AeroChamber Plus™ increased the peak plasma concentrations (C(max)) of BDP (2822.3 ± 1449.9 vs. 5454.9 ± 3197.1 pg ml(-1)), its active metabolite beclometasone 17-monopropionate (17-BMP) (771.6 ± 288.7 vs. 1138.9 ± 495.6 pg ml(-1)) and formoterol (38.4 ± 17.8 vs. 54.7 ± 20.0 pg ml(-1)).",Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21615456/),[pg] / [ml],54.7,128804,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,3.07,136756,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,6.21,136757,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,0.84,136758,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h·μM,1.50,136759,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136760,DB01274,Arformoterol
,19878590,plasma AUC,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136761,DB01274,Arformoterol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,2,136762,DB01274,Arformoterol
,19878590,AU,"Mean plasma AUC values were lower in COPD patients versus healthy subjects for budesonide (3.07 microM x hr versus 6.21 microM x hr) and fluticasone (0.84 microM x hr versus 1.50 microM x hr), and the dose-adjusted AUC (geometric mean) ratios in healthy subjects and patients with severe COPD for plasma budesonide and fluticasone were similar (2.02 versus 1.80; primary end point).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),,1,136763,DB01274,Arformoterol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,15.5,136764,DB01274,Arformoterol
,19878590,Tmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),min,50.8,136765,DB01274,Arformoterol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,4.41,136766,DB01274,Arformoterol
,19878590,mean residence time,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),h,12.78,136767,DB01274,Arformoterol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,1.08,136768,DB01274,Arformoterol
,19878590,Cmax,"In COPD patients, the Tmax and the mean residence time in the systemic circulation were shorter for budesonide versus fluticasone (15.5 min versus 50.8 min and 4.41 hrs versus 12.78 hrs, respectively) and Cmax was higher (1.08 microM versus 0.09 microM).",The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19878590/),μM,0.09,136769,DB01274,Arformoterol
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.11,138663,DB01274,Arformoterol
,18321744,minimum concentrations,"Formoterol caused a significantly greater decrease in serum potassium than BDP/formoterol or placebo (difference in mean minimum concentrations; 0.11 and -0.15 mmol/l, respectively, p<0.05 for both comparisons).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],-0.15,138664,DB01274,Arformoterol
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.4,138665,DB01274,Arformoterol
,18321744,maximum increase,"For glucose, the mean maximum increase after formoterol treatment was 0.4 mmol/l (p<0.01 compared to placebo), while BDP/formoterol treatment caused a maximum increase of 0.7 mmol/l (p<0.01 compared to formoterol and placebo).",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),[mM] / [l],0.7,138666,DB01274,Arformoterol
,18321744,elimination half-life,"The active metabolite of BDP is beclomethasone-17-monopropriate (B17MP), which reached Cmax at 0.25 h, with an elimination half-life of 3.7 h.",Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18321744/),h,3.7,138667,DB01274,Arformoterol
,7170790,elimination half-life,The elimination half-life of formoterol was 4-6 h in dogs and 1.7 h in rats.,"Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),h,4-6,142695,DB01274,Arformoterol
,7170790,elimination half-life,The elimination half-life of formoterol was 4-6 h in dogs and 1.7 h in rats.,"Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),h,1.7,142696,DB01274,Arformoterol
,7170790,Biliary excretion,"Biliary excretion after oral dosage amounted to 65 and 31% in rats and dogs, respectively.","Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),%,65,142697,DB01274,Arformoterol
,7170790,Biliary excretion,"Biliary excretion after oral dosage amounted to 65 and 31% in rats and dogs, respectively.","Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7170790/),%,31,142698,DB01274,Arformoterol
,10335908,maximum concentration (Cmax),"Mean with (SD; n = 12) of maximum concentration (Cmax) and area under the curve (AUC) of formoterol in plasma were 266 (108) pmol x l(-1) and 1330 (398) pmol x l(-1), respectively.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),[pM] / [l],266,154250,DB01274,Arformoterol
,10335908,area under the curve (AUC),"Mean with (SD; n = 12) of maximum concentration (Cmax) and area under the curve (AUC) of formoterol in plasma were 266 (108) pmol x l(-1) and 1330 (398) pmol x l(-1), respectively.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),[pM] / [l],1330,154251,DB01274,Arformoterol
,10335908,half-life (t1/2),A predominant slow elimination of formoterol from plasma with a mean half-life (t1/2) of 10 h was demonstrated.,Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,10,154252,DB01274,Arformoterol
,10335908,terminal half-lives,"The terminal half-lives calculated from the excretion rate-time curves, i.e., 13.9 h and 12.3 h for the (R,R)- and (S,S)-enantiomer, respectively, confirm the slow elimination of formoterol from plasma.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,13.9,154253,DB01274,Arformoterol
,10335908,terminal half-lives,"The terminal half-lives calculated from the excretion rate-time curves, i.e., 13.9 h and 12.3 h for the (R,R)- and (S,S)-enantiomer, respectively, confirm the slow elimination of formoterol from plasma.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,12.3,154254,DB01274,Arformoterol
,10335908,maximum QTc,The mean maximum QTc increase was 25 msec at 6 h.,Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),ms,25,154255,DB01274,Arformoterol
,10335908,terminal elimination half-life,"Due to a terminal elimination half-life of about 10 h, sustained systemic concentrations of formoterol are predicted for a twice daily treatment regimen without noteworthy accumulation.",Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10335908/),h,10,154256,DB01274,Arformoterol
,33152467,Cmax,The exception was that Cmax for glycopyrrolate was slightly lower in Asian versus Western subjects (0.6-0.7).,Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33152467/),,0.6-0.7,155773,DB01274,Arformoterol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,34.08,176657,DB01274,Arformoterol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,30.86,176658,DB01274,Arformoterol
,20109122,lung deposition,"The average lung deposition of BDP/formoterol was 34.08 +/- 9.30% (relative to nominal dose) in healthy subjects, 30.86 +/- 8.89% in asthmatics, and 33.10 +/- 8.90% in COPD patients.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,33.10,176659,DB01274,Arformoterol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,53.48,176660,DB01274,Arformoterol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,57.64,176661,DB01274,Arformoterol
,20109122,Extrathoracic deposition,"Extrathoracic deposition was 53.48% +/- 8.95, 57.64% +/- 9.92 and 54.98% +/- 7.01, respectively.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),%,54.98,176662,DB01274,Arformoterol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.42,176663,DB01274,Arformoterol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.96,176664,DB01274,Arformoterol
,20109122,C/P ratios,"C/P ratios of 1.42 +/- 0.32 in healthy subjects, 1.96 +/- 0.43 in asthmatics, and 1.94 +/- 0.69 for COPD patients confirmed drug distribution to all regions of the lungs.","Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109122/),,1.94,176665,DB01274,Arformoterol
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1598.38,202225,DB01274,Arformoterol
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1657.09,202226,DB01274,Arformoterol
,29901860,area under the plasma drug concentration-time curve 0-12 hours (AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],1276.75,202227,DB01274,Arformoterol
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.16,202228,DB01274,Arformoterol
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],39.53,202229,DB01274,Arformoterol
,29901860,AUC0-12,"Systemic budesonide exposure (primary objective) based on area under the plasma drug concentration-time curve 0-12 hours (AUC0-12 ; % coefficient of variation) was 1598.38 (49.7), 1657.09 (50.4), and 1276.75 (70.4) pg·h/mL for BGF MDI, BFF MDI, and BUD/FORM DPI, respectively; and formoterol exposure (AUC0-12 [% coefficient of variation]) was 39.16 (45.9), 39.53 (40.5), and 23.24 (59.2) pg·h/mL, respectively.","Pharmacokinetics of Co-Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed-Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single-Dose, Crossover Study in Healthy Adults. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29901860/),[h·pg] / [ml],23.24,202230,DB01274,Arformoterol
,10665129,peak FEV1 change,"Mean peak FEV1 change (primary endpoint) was maximum with the administration of the combination of ipratropium and formoterol (335.2 ml, SE 24.6), and it differed significantly from the observed peak changes following single administration of the two tested doses of ipratropium (p < 0.05 and p < 0.05 respectively).","Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665129/),ml,335.2,209358,DB01274,Arformoterol
,31332649,time to peak FEV1 response,"The average time to peak FEV1 response was 3.94 h (standard deviation 2.75), while the standardized area under the response-time curve from 0 to 12 h for FEV1 was 2.72 (standard deviation 1.84).","Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332649/),h,3.94,210517,DB01274,Arformoterol
,31332649,area under the response-time curve from 0 to 12 h,"The average time to peak FEV1 response was 3.94 h (standard deviation 2.75), while the standardized area under the response-time curve from 0 to 12 h for FEV1 was 2.72 (standard deviation 1.84).","Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31332649/),,2.72,210518,DB01274,Arformoterol
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,97.9,224437,DB01274,Arformoterol
,18623040,AUC ratios,Study II: AUC ratios were 97.9% (budesonide) and 82.2% (formoterol) (budesonide/formoterol pMDI versus budesonide pMDI+formoterol DPI).,"Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18623040/),%,82.2,224438,DB01274,Arformoterol
,31397184,FVC,"Maximum FEV1 and FVC changes were measured as 0.25/0.41 L, 0.32/0.49 L, and 0.37/0.53 L, for TIOmono, TIO/FORMbid, and TIO/FORMfixed, respectively (FEV1: TIO/FORMfixed vs TIOmono, p = 0.0017 and TIO/FORMfixed vs TIO/FORMbid, p = 0.4846); no differences were recorded between the combination groups.","Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31397184/),l,0.49,229895,DB01274,Arformoterol
,31397184,FVC,"Maximum FEV1 and FVC changes were measured as 0.25/0.41 L, 0.32/0.49 L, and 0.37/0.53 L, for TIOmono, TIO/FORMbid, and TIO/FORMfixed, respectively (FEV1: TIO/FORMfixed vs TIOmono, p = 0.0017 and TIO/FORMfixed vs TIO/FORMbid, p = 0.4846); no differences were recorded between the combination groups.","Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31397184/),l,0.37,229896,DB01274,Arformoterol
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,95,243682,DB01274,Arformoterol
,31841699,accumulation ratio,"In the phase I PK study (30 patients), budesonide and glycopyrronium Cmax were comparable after single and chronic dosing of BGF MDI (accumulation ratio [RAC] 95% and 107%, respectively) whereas Cmax for formoterol was slightly higher after chronic dosing (RAC 116%).",Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841699/),%,107,243683,DB01274,Arformoterol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.51,252557,DB01274,Arformoterol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.62,252558,DB01274,Arformoterol
,15373928,PD20,"Geometric mean PD20 values were 0.51 mg with HFA, 0.62 mg with DPI, 0.62 mg with CFC and 0.2 mg with placebo.","Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373928/),mg,0.2,252559,DB01274,Arformoterol
